The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...
Two decades ago, Professor Shao-Cong Sun first discovered the non-canonical NF-κB pathway mediated by NF-κB-inducing kinase (NIK). Since then, more ...
CD25 expression has long been recognized as an adverse prognostic marker in acute leukemias including acute myeloid leukemia ...
A new King’s College London study finds a cancer drug may reverse brain connectivity changes linked to early Alzheimer’s ...
In a cohort study of nearly 16,000 US patients with breast cancer who were prescribed a cyclin-dependent kinase (CDK) 4/6 inhibitor, only 46% underwent liver function testing in the 2 weeks before ...
The impact of neflamapimod on neurofilament light levels will be examined in a study of approximately 35 patients with ALS, facilitated by the EXPERTS-ALS platform, according to a press release from ...
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Background Concomitant metabolic dysfunction-associated steatotic liver disease (MASLD) is prevalent in patients with chronic ...
Solid Biosciences’ SGT-003 is the only late‑stage program to show early cardiac benefit across biomarkers and function, according to William Blair.
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results